American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for 103palladium brachytherapy
暂无分享,去创建一个
Ravinder Nath | Colin G. Orton | J. Blasko | W. Butler | G. Merrick | S. Nag | D. Beyer | C. Orton | R. Nath | Subir Nag | John C. Blasko | Gregory S. Merrick | Wayne M. Butler | David C. Beyer
[1] H. Ragde,et al. Brachytherapy for clinically localized prostate cancer. , 2000, Seminars in surgical oncology.
[2] R Nath,et al. Dosimetric prerequisites for routine clinical use of new low energy photon interstitial brachytherapy sources. Recommendations of the American Association of Physicists in Medicine Radiation Therapy Committee. Ad Hoc Subcommittee of the Radiation Therapy Committee. , 1998, Medical physics.
[3] J F Williamson,et al. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription. , 2000, Medical physics.
[4] Robert E. Wallace,et al. Dosimetric characterization of a new design 103 palladium brachytherapy source. , 1999, Medical physics.
[5] L. Anderson,et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .
[6] A. Cantor,et al. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. , 1998, Urology.
[7] K. Wallner,et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. , 1999, International journal of radiation oncology, biology, physics.
[8] Z. Chen,et al. Long-term complications with prostate implants: iodine-125 vs. palladium-103. , 1999, Radiation oncology investigations.
[9] 125-Iodine/103-Palladium brachytherapy with or without neoadjuvant androgen ablation for early stage prostate cancer , 2000 .
[10] W. Butler,et al. Temporal resolution of urinary morbidity following prostate brachytherapy. , 2000, International journal of radiation oncology, biology, physics.
[11] J. Williamson,et al. Monte Carlo modeling of the transverse-axis dose distribution of the model 200 103Pd interstitial brachytherapy source. , 2000, Medical physics.
[12] R Nath,et al. Measurement of dose-rate constant for 103Pd seeds with air kerma strength calibration based upon a primary national standard. , 2000, Medical physics.
[13] W Cavanagh,et al. Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up. , 1997, Seminars in surgical oncology.
[14] W Cavanagh,et al. Palladium-103 brachytherapy for prostate carcinoma. , 2000, International journal of radiation oncology, biology, physics.
[15] K. Wallner,et al. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. , 1996, International journal of radiation oncology, biology, physics.
[16] G. Ibbott,et al. On the use of apparent activity (Aapp) for treatment planning of 125I and 103Pd interstitial brachytherapy sources: recommendations of the American Association of Physicists in Medicine radiation therapy committee subcommittee on low-energy brachytherapy source dosimetry. , 1999, Medical physics.
[17] P. Grimm,et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.
[18] W. Butler,et al. Rectal dosimetric analysis following prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.
[19] S Nag,et al. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. , 1995, Urology.